Oncotarget

Research Papers:

Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis

Yao-Fan Fang, Yen-Fu Chen, Ting-Ting Chung, Lai-Chu See, Kuang-Hui Yu, Shue-Fen Luo, Chang-Fu Kuo and Jenn-Haung Lai _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:80461-80471. https://doi.org/10.18632/oncotarget.19057

Metrics: PDF 1400 views  |   HTML 1556 views  |   ?  


Abstract

Yao-Fan Fang1, Yen-Fu Chen1, Ting-Ting Chung1, Lai-Chu See2, Kuang-Hui Yu1, Shue-Fen Luo1, Chang-Fu Kuo1,3,4 and Jenn-Haung Lai1,5

1Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

2Biostatistics Core Laboratory, Molecular Medicine Research Centre, Chang Gung University, Taoyuan, Taiwan

3Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, England

4Big Data Research Office, Chang Gung Memorial Hospital, Taoyuan, Taiwan

5Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Correspondence to:

Jenn-Haung Lai, email: laiandho@gmail.com

Chang-Fu Kuo, email: zandis@gmail.com

Keywords: Sjögren syndrome, hydroxychloroquine, cancer, epidemiology, pharmacoepidemiology

Received: April 26, 2017     Accepted: June 19, 2017     Published: July 06, 2017

ABSTRACT

Hydroxychloroquine inhibits systemic inflammation and autophagy and may thus have antineoplastic effects [1]. We investigated the effect of hydroxychloroquine on cancer risk in patients with primary Sjögren syndrome(pSS). We used the Taiwan National Health Insurance Database to compare cancer incidence between incident pSS patients with or without at least 6-month hydroxychloroquine use within a 1- or 3-year period. Propensity score matched landmark analysis was used. We included 4194 alive patients without cancer 1 year after pSS diagnosis from 2000 through 2005. The propensity score matched 1148 patients with at least 6-month hydroxychloroquine exposure at 1 year after diagnosis and 1148 patients without. Median follow-up after the 1-year landmark was 6 years. During follow up 62 hydroxychloroquine users and 56 non-hydroxychloroquine users developed cancer. Kaplan–Meier estimates showed no difference in overall survival between hydroxychloroquine users and non-users in the 1-year. Hydroxychloroquine was associated with a hazard ratio (HR) of 1.11 (95% CI, 0.78–1.60) in 1-year landmark analysis. In 3-year landmark analysis, hydroxychloroquine was associated with a HR for cancer of 1.37 (95% CI, 0.97–1.94). This propensity score matched landmark analysis of Taiwanese patients with incident pSS found that hydroxychloroquine was not associated with cancer risk nor protection.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19057